This is a working overview of drug affinity complex, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-05 and is reviewed periodically as new material appears.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
== Biography == Langevin received an MD degree from McGill University in 1978. She did a post doctoral research fellowship in Neurochemistry at the MRC Neurochemical Pharmacology Unit in Cambridge, England, a residency in Internal Medicine and a fellowship in Endocrinology and Metabolism at Johns Hopkins Hospital. She was a Professor in Residence of Medicine at Harvard Medical School, Brigham and Women's Hospital. She was also a part-time Professor of Neurology, Orthopedics and Rehabilitation at the University of Vermont College of Medicine. She was the Principal Investigator of two NIH-funded studies investigating the role of connective tissue in low back pain and the mechanisms of manual and movement based therapies. Her previous studies in humans and animal models have found that "needle grasp", the biomechanical component of de qi, may be caused by connective tissue winding around the needle. Helene Langevin was appointed as Director of the Osher Center for Integrative Medicine at Harvard Medical School and Brigham and Women's Hospital in November 2012.
=== The World Health Organization === The World Health Organization considers two formulation bioequivalent if the 90% confidence interval for the ratio multisource (generic) product/comparator lie within 80.00–125.00% acceptance range for AUC0–t and Cmax. For high variable finished pharmaceutical products, the applicable acceptance range for Cmax can be expanded (up to 69.84–143.19%).
Ochronosis is a medical condition characterized by the accumulation of homogentisic acid in connective tissues, leading to pigmentation changes. The term derives from the yellowish-brown (ocher-like) discoloration observed in histological samples. However, macroscopically, the affected tissues often appear bluish-grey due to the Tyndall effect, a phenomenon in which scattered light gives deeper-lying pigments a blue hue. Ochronosis is most commonly associated with the rare metabolic disorder alkaptonuria, a genetic condition involving homogentisic acid oxidase deficiency. It may also occur as an acquired condition, known as exogenous ochronosis, resulting from prolonged topical application or systemic exposure to certain phenol derivatives, particularly hydroquinone. The condition was first described by German pathologist Rudolf Virchow in 1865.
Sangeeta N. Bhatia (born June 24, 1968) is an American inventor, professor, and entrepreneur who holds both medical and engineering training. She holds multiple appointments and directs substantial research programs at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts She is reported to be the first woman physician-scientist to be elected to all five of the United States' National Academies.
Sources: en.wikipedia.org
=== Attention-deficit hyperactivity disorder === One in four people who have a substance use disorder also have attention-deficit hyperactivity disorder, which makes the treatment of both conditions more difficult. ADHD is associated with an increased craving for drugs. Having ADHD makes it more likely that an individual will initiate substance misuse at a younger age than their peers. They are also more likely to experience poorer outcomes, such as longer time to remission, and to have increased psychiatric complications from substance misuse. While generally stimulant medications do not seem to worsen substance use, they are known to be non-medically used in some cases. Psychosocial therapy and/or nonstimulant medications and extended release stimulants are ADHD treatment options that reduce these risks.
2 O−2 + 2 H+ → O2 + H2O2 2 H2O2 → O2 + 2 H2O Peroxisomes are organelles found in virtually all eukaryotic cells. They are involved in the catabolism of very long chain fatty acids, branched chain fatty acids, D-amino acids, polyamines, and biosynthesis of plasmalogens and ether phospholipids, which are found in mammalian brains and lungs. They produce hydrogen peroxide in a process catalyzed by flavin adenine dinucleotide (FAD):
== Awards and honours == 1995: Max-Bergmann-Medal of the MBK Society 2004: Josef Rudinger Award of the European Peptide Society 2011: Doctor honoris causa, University of Cergy-Pontoise, Paris 2018: Akabori Memorial Lecture Award of the Japanese Peptide Society 2020: Ernesto Scoffone Award of the Italian Peptide Society
Sources: en.wikipedia.org
The siege of Coimbra in 1064 or the definitive conquest of Coimbra by Christian forces took place in 1064, from January to July; it ended on 9 July 1064, a Friday, when the king, Ferdinand I of Leon, captured the city from the Muslims. The city of Coimbra had previously been taken from the Christians by Almanzor (or al-Manṣūr) in 987. When the Fitna of al-Andalus broke out and the Umayyad Caliphate of Cordova fragmented into numerous taifa states, Dom Sesnando Davides, lord of Tentúgal proposed the conquest of the city to Ferdinand of Leon. Ferdinand thus began preparations for the campaign in December 1063, after receiving the remains of Saint Isidore of Seville in León. Before he moved against Coimbra however, he made a pilgrimage to Santiago de Compostela. Having prayed there before the tomb of the apostle, St. James of Compostela, for three days and made several donations to the church there, he departed accompanied by his wife Dona Sancha, his sons, the Bishop Crescónio of Santiago, Bishop Vistruário of Lugo, Bishop Suário of Mondonhedo, Bishop Sesnando of Portugal, the abbot Ariano of Cela Nova, abbot Pedro of Guimarães, and a large number of nobles. They advanced through a coastal road that linked Santiago de Compostela to Iria Flavia to Braga, Porto and Coimbra. They arrived before the walls of the city on 20 January 1064. The Muslim garrison fiercely resisted the Christian attacks. The supply situation of the Christians was not favourable and Ferdinand even pondered lifting the siege.
Since radon is a colorless, odorless gas, the only way to know how much is present in the air or water is to perform tests. In the US, radon test kits are available to the public at retail stores, such as hardware stores, for home use, and testing is available through licensed professionals, who are often home inspectors. Efforts to reduce indoor radon levels are called radon mitigation. In the US, the EPA recommends all houses be tested for radon. In the UK, under the Housing Health & Safety Rating System, property owners have an obligation to evaluate potential risks and hazards to health and safety in a residential property. Alpha-radiation monitoring over the long term is a method of testing for radon that is more common in countries outside the United States.
== Medical uses == Stimulants are widely used throughout the world as prescription medicines as well as without a prescription (either legally or illicitly) as performance-enhancing or recreational drugs. Stimulants produce a noticeable crash or comedown at the end of their effects. In the US, the most frequently prescribed stimulants as of 2013 were lisdexamfetamine (Vyvanse), methylphenidate (Ritalin), and amphetamine (Adderall). It was estimated in 2015 that the percentage of the world population that had used cocaine during a year was 0.4%. For the category "amphetamines and prescription stimulants" (with "amphetamines" including amphetamine and methamphetamine) the value was 0.7%, and for MDMA 0.4%. Stimulants have been used in medicine for many conditions including obesity, sleep disorders, mood disorders, impulse-control disorders, asthma, nasal congestion and, in case of cocaine, as local anesthetics. Drugs used to treat obesity are called anorectics and generally include drugs that follow the general definition of a stimulant, but other drugs such as cannabinoid receptor antagonists also belong to this group. Eugeroics are used in management of sleep disorders characterized by excessive daytime sleepiness, such as narcolepsy, and include stimulants such as modafinil and pitolisant. Stimulants are used in impulse control disorders such as ADHD and off-label in mood disorders such as major depressive disorder to increase energy, focus, and elevate mood.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.